Serotonin uptake is required for Rac1 activation in Kras‐induced acinar‐to‐ductal metaplasia in the pancreas. Issue 3 (4th October 2018)

• Record Type: Journal Article
• Authors: Saponara, Enrica; Visentin, Michele; Baschieri, Francesco; Seleznik, Gitta; Martinelli, Paola; Esposito, Irene; Buschmann, Johanna; Chen, Rong; Parrotta, Rossella; Borgeaud, Nathalie; Bombardo, Marta; Malagola, Ermanno; Caflisch, Amedeo; Farhan, Hesso; Graf, Rolf; Sonda, Sabrina
• Is Part Of: Journal of pathology. Volume 246:Issue 3(2018)
• Page Start: 352
• Page End: 365
• Publication Date: 2018-10-04
• Subjects: serotonin -- Rac1 -- acinar‐to‐ductal metaplasia -- pancreatic cancer; Pathology -- Periodicals; 616.07
• DOI: 10.1002/path.5147
• Languages: English
• ISSNs: 0022-3417

Abstract

Abstract: Pancreatic ductal adenocarcinoma (PDAC), which is the primary cause of pancreatic cancer mortality, is poorly responsive to currently available interventions. Identifying new targets that drive PDAC formation and progression is critical for developing alternative therapeutic strategies to treat this lethal malignancy. Using genetic and pharmacological approaches, we investigated in vivo and in vitro whether uptake of the monoamine serotonin [5‐hydroxytryptamine (5‐HT)] is required for PDAC development. We demonstrated that pancreatic acinar cells have the ability to readily take up 5‐HT in a transport‐mediated manner. 5‐HT uptake promoted activation of the small GTPase Ras‐related C3 botulinum toxin substrate 1 (Rac1), which is required for transdifferentiation of acinar cells into acinar‐to‐ductal metaplasia (ADM), a key determinant in PDAC development. Consistent with the central role played by Rac1 in ADM formation, inhibition of the 5‐HT transporter Sert ( Slc6a4 ) with fluoxetine reduced ADM formation both in vitro and in vivo in a cell‐autonomous manner. In addition, fluoxetine treatment profoundly compromised the stromal reaction and affected the proliferation and lipid metabolism of malignant PDAC cells. We propose that Sert is a promising therapeutic target to counteract the early event of ADM, with the potential to stall the initiation and progression of pancreatic carcinogenesis. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.